SYNB1353

About Synlogic

Synlogic Therapeutics is a clinical-stage biotech company developing Synthetic Biotics—engineered living microbes designed as targeted, orally administered therapeutics. The company's mission is to leverage synthetic biology to create transformative treatments for diseases with high unmet need, such as Phenylketonuria (PKU) and Homocystinuria (HCU). Its strategy involves advancing its modular platform through clinical proof-of-concept, though it currently faces significant financial and execution risks as a micro-cap public entity. Recent pipeline prioritization and workforce reductions reflect a focused but constrained operational strategy.

Therapeutic Areas